시장보고서
상품코드
1307858

경동맥 질환(CAD) 시장 : 1차 조사(KOL의 인사이트) - 시장 인텔리전스 - 역학과 시장 예측(-2033년) [CEA, CAS, TCAR 시술 시장]

Carotid Artery Disease (CAD)| Primary Research (KOL´s Insight) | Market Intelligence | Epidemiology & Market Forecast-2033 [CEA, CAS & TCAR Procedure Market]

발행일: | 리서치사: Mellalta Meets LLP | 페이지 정보: 영문 246 Pages | 배송안내 : 즉시배송


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

경동맥 질환(CAD) 시장은 CAD의 유병률 상승과 보다 효과적이며 편리성 높은 치료 옵션의 필요성에 의해 대폭적인 성장이 전망됩니다. 유병률의 상승과 시장 규모의 확대, 혁신적인 치료법의 도입이 예측되는 것으로 인해 CAD 시장은 제약기업 및 의료기관에 유리한 기회를 제공하고 있습니다. 미국, 유럽 5개국, 일본의 G7 국가가 CAD 치료 시장을 현재 독점하고 있습니다. 2033년까지 이 국가들의 시장 규모는 2019년 24억 달러에서 대폭 증가하며, 안정된 CAGR이 전망됩니다. 2019년의 시장 점유율은 미국이 19억 달러로 최대였으며, 이어서 유럽 5개국이 3억 달러, 일본이 1억 5,000만 달러를 기록했습니다. 새로운 치료법의 등장에 의해 시장 전체는 2033년까지 확대할 것으로 예상되고 있습니다.

세계의 경동맥 질환(CAD) 시장에 대해 조사했으며, 시장 현황과 함께 증례 수의 동향, 환자 동향, 경쟁 제품의 시장 포지셔닝, 시장의 기회 등을 제공하고 있습니다.

목차

주요 요약

경동맥 질환 배경

경동맥 질환 진단

  • 경동맥 질환(CAD) : 진단의 개요
  • 2021년 혈관 외과 학회(SVS) 진단 가이드라인

역학과 환자 집단

  • 주요 조사 결과
  • 메소드와 데이터 소스

경동맥 질환의 역학과 모델 파라미터의 주요 정보원

  • 미국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

현재의 의료 행위

출시 디바이스

  • 출시 및 신규 스텐트의 개요
  • Acculink(Abbott)
  • Xact(Abbott)
  • PRECISE PRO RX Nitinol Stent System(Cordis)
  • Protege RX(Medtronic)
  • CGuardEPS(Inspire MD)
  • Neuroguard IEP(Contego Medical)
  • Carotid WALLSTENT(Boston Scientific)
  • ENROUTE Transcarotid Stent System(SilkRoad Medical)
  • MER(Balton)
  • Casper/Roadsaver(Microvention-Terumo, Inc.)

미충족 요구

경동맥 질환 분야의 파이프라인 개발

  • 제품 분석
    • CGuard Prime(Inspire MD)
    • 쇼트 샤프트 C 가드(Inspire MD)

경동맥 질환(CAD) - 가격결정과 상환 연구

경동맥 질환(CAD) - 경쟁 포지셔닝

시장 전망

  • 주요 조사 결과
  • 개요
  • 2033년까지의 국가별 시장 예측

국가별 시장 예측

  • 미국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

시장 촉진요인과 억제요인

부록

KSA 23.07.26

The Carotid Artery Disease (CAD) market is undergoing substantial growth and transformation, driven by the increasing prevalence of CAD and the need for more effective and convenient treatment options. With the projected rise in prevalent cases and market size, as well as the introduction of innovative therapies, the CAD market presents lucrative opportunities for pharmaceutical companies and healthcare providers. In terms of geographical distribution, the G7 countries-United States, European five countries, and Japan-currently dominate the CAD therapy market. By 2033, the market size in these countries will significantly increase from USD 2.4 billion in 2019, with a steady CAGR. In 2019, the United States held the largest market share at USD 1.9 billion, followed by the European five countries at USD 0.3 billion and Japan at USD 0.15 billion. With the advent of new therapies, the overall market is expected to expand by 2033.

"Personally speaking, I think that it is absolutely essential that we identify criteria for defining patients who are at high risk for stroke with an asymptomatic carotid stenosis in whom we should target CEA or CAS. In the US, over 90% of carotid interventions are performed in asymptomatic patients (120,000 per year). However, if we assume that the 1995 ACAS (Asymptomatic Carotid Atherosclerosis Study) data still have any relevance in 2013 (although it probably does not), 95% of all carotid interventions in asymptomatic patients are ultimately unnecessary. Even if the procedural risk of CEA and CAS could be reduced to zero, 93% of all interventions would still be unnecessary."

Carotid stenosis/ carotid artery disease (CAD) is caused by a buildup of plaque (atherosclerosis) inside the artery wall that reduces blood flow to the brain. Older people are more likely to be affected by carotid stenosis. Before age 75, men are more at risk than women. A person who has high cholesterol, has high blood pressure, and smokes is eight times more likely to develop atherosclerosis than a person without these risk factors. Carotid artery disease develops slowly. If it increases to the point that a carotid artery is blocked, or blood flow is otherwise seriously reduced, a stroke can occur.

The primary goal in treating carotid artery disease is to prevent stroke. The choice of treatment depends on the degree of blockage in the carotid arteries, whether the blockage is causing symptoms, and the age and overall health of the individual. For those with mild to moderate blockage, lifestyle changes to slow the accumulation of fatty deposits and medications to control blood pressure or lower cholesterol are often recommended. In cases of severe blockage or for individuals who have experienced a Transient Ischemic Attack (TIA) or stroke, removal of the blockage might be necessary. The most common procedures are Carotid Endarterectomy (CEA) and Carotid Angioplasty and Stenting (CAS). Many patients with asymptomatic CAD do not receive any medical treatment.

Carotid Artery Disease (CAD) -Epidemiology

The total prevalent cases of Carotid Artery Disease (CAD) in the G7 countries are projected to increase from 11.45 million in 2019 to 2033 with a CAGR of 0.6% for the study period (2019-2033 ). According to estimates, the United States accounted for the highest incidence of Carotid Artery Disease (CAD) cases during the study period. Among the EU5, Germany had the highest cases of Carotid Artery Disease (CAD), followed by UK, France, Italy, and Spain. Japan is reported to have the highest number of cases after the United States.

Procedural Insights Carotid endarterectomy (CEA) and carotid artery stenting (CAS) are well-established treatments for CAD. However, their usage varies by region, with CEA being the preferred option in most areas due to its longer track record and proven efficacy. The introduction of newer procedures like Transcarotid Artery Revascularization (TCAR) has added to the treatment landscape, although its adoption is currently limited. Based on insights from Key Opinion Leaders (KOLs), diagnosis and treatment rates are expected to improve with increased awareness and access to better diagnostic tools and treatment options.

Carotid Artery Disease (CAD) - Current Market Size & Forecast Trends

The G7 therapeutic market for Carotid Artery Disease (CAD) is on a trajectory of significant growth from 2019 to 2033. Driven by an increase in the application and enhancement of existing treatment methods such as Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), and Transcarotid Artery Revascularization (TCAR) and the launch of new products, this market is expected to expand from USD 2.4 billion in 2019. Emerging devices are expected to be launched in the Carotid Artery Disease CAS and TCAR space and will contribute to the increase in devices market share in the CAS and TCAR setting. Specifically, Inspire MD is introducing their second-generation devices for CAS, the CGuard Prime, and for TCAR, the Short Shaft CGuard, which are expected to further contribute to the overall market's growth.

The use of procedures like Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), and Transcarotid Artery Revascularization (TCAR) to treat Carotid Artery Disease (CAD) is expected to increase significantly in the coming years. The reasons for this growth include an aging population, which leads to a higher prevalence of CAD, technological advances that make these procedures safer and more efficient, improved patient outcomes due to better procedural techniques and patient selection, higher healthcare expenditure by nations, and greater awareness leading to early detection of CAD.

The CAD market is further split by devices/procedures, with the Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS), and Transcarotid Artery Revascularization (TCAR) markets expected to experience significant growth by 2033, reflecting substantial market expansion.

Report Highlights:

  • Carotid Artery Disease (CAD) - Current Market Trends
  • Carotid Artery Disease (CAD) - Market Opportunities and Sales Potential for Agents
  • Carotid Artery Disease (CAD) - Patient-based Market Forecast to 2033
  • Carotid Artery Disease (CAD) - Untapped Business Opportunities
  • Carotid Artery Disease (CAD) - Product Positioning Vis-a-vis Competitors' Products
  • Carotid Artery Disease (CAD) - KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Carotid Artery Disease Background

  • Carotid Artery Disease Definition
  • Overview Flow Diagram
  • Causes
  • Risk Factors
  • Signs & Symptoms
  • Pathophysiology
  • Staging

Carotid Artery Disease Diagnosis

  • Carotid Artery Disease (CAD): Diagnosis Overview
  • 2021 Society for Vascular Surgery (SVS) Diagnostic Guidelines

Epidemiology and Patient Populations

  • Key Findings
  • Methods and data Sources
    • Total G7 Prevalent cases of Carotid Artery Disease
    • Total G7 Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]

Key Sources for Carotid Artery Disease Epidemiology and Model Parameters

  • United States
    • United States Prevalent cases of Carotid Artery Disease
    • United States Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • Germany
    • Germany Prevalent cases of Carotid Artery Disease
    • Germany Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • France
    • France Prevalent cases of Carotid Artery Disease
    • France Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • Italy
    • Italy Prevalent cases of Carotid Artery Disease
    • Italy Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • Spain
    • Spain Prevalent cases of Carotid Artery Disease
    • Spain Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • United Kingdom
    • United Kingdom Prevalent cases of Carotid Artery Disease
    • United Kingdom Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]
  • Japan
    • Japan Prevalent cases of Carotid Artery Disease
    • Japan Diagnosed, Treated, and Deemed High Risk Cases of Carotid Artery Disease
    • Cases by procedure Type [carotid endarterectomy (CEA), carotid artery stenting (CAS), and transcarotid artery revascularization (TCAR)]

Current Medical Practice

  • Carotid Revascularization Devices Explanations: CEA, CAS & TCAR
  • Guidelines
    • 2021 Society for Vascular Surgery (SVS) clinical practice guidelines
    • European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines
    • Key Difference between SVS and ESVS Treatment Guidelines
    • 2021 Japan Stroke Society Guideline

Marketed Devices Chapters

  • Summary of Marketed & Emerging Stents
  • Acculink (Abbott)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • Xact (Abbott)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • PRECISE PRO RX Nitinol Stent System (Cordis)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • Protégé RX (Medtronic)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • CGuardEPS (Inspire MD)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • Neuroguard IEP (Contego Medical)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • Carotid WALLSTENT (Boston Scientific)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • ENROUTE Transcarotid Stent System (SilkRoad Medical)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • MER (Balton)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033
  • Casper/Roadsaver (Microvention-Terumo, Inc.)
    • Product Profile
    • Clinical Profile
    • Sales & Forecast to 2033

Unmet Needs

Pipeline Developments in the Carotid Artery Disease space

  • Product Analysis
    • CGuard Prime (Inspire MD)
      • Product Profile
      • Clinical Development
      • Market & Sales Opportunity Forecasted to 2033
    • Short Shaft CGuard (Inspire MD)
      • Product Profile
      • Clinical Development
      • Market & Sales Opportunity Forecasted to 2033

Carotid Artery Disease (CAD)- Pricing and Reimbursement Studies

  • Fixed and variable cost of carotid endarterectomy and stenting in the United States: A comparative study
  • Comparative Analysis of the estimated cost profiles of TCAR, TF-CAS, and CEA

Carotid Artery Disease (CAD)- Competitive Positioning

  • Future Treatment Paradigm
  • Carotid Artery Disease (CAD) Competitor Landscape and Approvals Anticipated
  • Annual Cost of CEA, CAS and TCAR procedures

Market Outlook

  • Key Findings
  • Overview
  • Country Specific Market Forecast to 2033
    • Total Market of Carotid Artery Disease (2019-2033)
      • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
      • Market Share of Carotid Artery Disease by Companies and CAS & TCAR Devices (2019-2033)
    • Total Market of Carotid Artery Disease (2019-2033)
      • Market Share of Carotid Artery Disease by Company for carotid endarterectomy (CEA) Procedures (2019-2033)
      • Market Share of Carotid Artery Disease by Company for carotid artery stenting (CAS) Procedures (2019-2033)
      • Market Share of Carotid Artery Disease by Company for carotid endarterectomy (CEA) Procedures (2019-2033)

Market Forecast by Country

  • United States
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Companies and CAS & TCAR Devices (2019-2033)
  • Germany
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Companies and CAS & TCAR Devices (2019-2033)
  • France
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
    • Market Share of Carotid Artery Disease by Companies (2019-2033)
  • Italy
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
    • Market Share of Carotid Artery Disease by Companies (2019-2033)
  • Spain
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
    • Market Share of Carotid Artery Disease by Companies (2019-2033)
  • United Kingdom
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
    • Market Share of Carotid Artery Disease by Companies (2019-2033)
  • Japan
    • Total Market of Carotid Artery Disease (2019-2033)
    • Market Share of Carotid Artery Disease by Surgical Procedures (2019-2033)
    • Market Share of Carotid Artery Disease by Companies (2019-2033)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Carotid Artery Disease?
  • What Factors Are Constraining the Market for Carotid Artery Disease?

Appendix

  • Methodology
  • 2020 AWMF Guidelines: Diagnostic Recommendations
  • 2023 ESVS European Treatment Guidelines
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제